Elizabeth Fox1,2, Christine Busch3, Alexander DeBernardo3,4, Blair Segers3,5, Joseph Gottschalk3,6, Richard Womer3, Naomi Balamuth3, Rochelle Bagatell3, Frank Balis3. 1. Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. elizabeth.fox@stjude.org. 2. St Jude Children's Research Hospital, Memphis, TN, 38105, USA. elizabeth.fox@stjude.org. 3. Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. 4. School of Dentistry, University of Texas Health Science Center, Houston, TX, USA. 5. St Jude Children's Research Hospital, Memphis, TN, 38105, USA. 6. University of New England College of Osteopathic Medicine, Biddeford, ME, USA.
Abstract
PURPOSE: High dose methotrexate (HDMTX) acute kidney injury (AKI) results in prolonged hospitalization and treatment delays. Using a pharmacologically-based approach, HDMTX was administered with standard combination therapy to patients with osteosarcoma; nephrotoxicity was assessed. METHODS: Patients were randomized by cycle to 4 h or 12 h HDMTX (12 g/m2) infusions administered with hydration, alkalization and leucovorin rescue. Urinalysis, AKI biomarkers, and estimated glomerular filtration rate using serum creatinine or cystatin C (GFRCr or GFRcysC) were obtained. Serum and urine methotrexate concentrations [MTX] were measured. RESULTS: Patients (n = 12), median (range) age 12.4 (5.7-19.2) years were enrolled; 73 MTX infusions were analyzed. Median (95% Confidence Interval) serum and urine [MTX] were 1309 (1190, 1400) µM and 16.4 (14.7, 19.4) mM at the end of 4 h infusion and 557 (493, 586) µM and 11.1 (9.9, 21.1) mM at the end of 12 h infusion. Time to serum [MTX] < 0.1 µM was 83 (80.7, 90.7) h and 87 (82.8, 92.4) h for 4 and 12 h infusions. GFRCr was highly variable, increased after cisplatin, and exceeded 150 ml/min/1.73 m2. GFRcysC was less variable and decreased at the end of therapy. AKI biomarkers were elevated indicating acute tubular dysfunction, however, did not differ between 4 and 12 h infusions. Radiographic and histological response were similar for patients receiving 4 h or 12 h infusions; the median percent tumor necrosis was > 95%. CONCLUSIONS: Reducing peak serum and urine MTX concentration by prolonging the infusion duration did not alter risk of acute kidney injury. GFRcysC was decreased at the end of therapy. Proteinuria and elevations in AKI biomarkers indicate that direct tubular damage contributes to HDMTX nephrotoxicity. CLINICAL TRIAL: NCT01848457.
RCT Entities:
PURPOSE: High dose methotrexate (HDMTX) acute kidney injury (AKI) results in prolonged hospitalization and treatment delays. Using a pharmacologically-based approach, HDMTX was administered with standard combination therapy to patients with osteosarcoma; nephrotoxicity was assessed. METHODS:Patients were randomized by cycle to 4 h or 12 h HDMTX (12 g/m2) infusions administered with hydration, alkalization and leucovorin rescue. Urinalysis, AKI biomarkers, and estimated glomerular filtration rate using serum creatinine or cystatin C (GFRCr or GFRcysC) were obtained. Serum and urine methotrexate concentrations [MTX] were measured. RESULTS:Patients (n = 12), median (range) age 12.4 (5.7-19.2) years were enrolled; 73 MTX infusions were analyzed. Median (95% Confidence Interval) serum and urine [MTX] were 1309 (1190, 1400) µM and 16.4 (14.7, 19.4) mM at the end of 4 h infusion and 557 (493, 586) µM and 11.1 (9.9, 21.1) mM at the end of 12 h infusion. Time to serum [MTX] < 0.1 µM was 83 (80.7, 90.7) h and 87 (82.8, 92.4) h for 4 and 12 h infusions. GFRCr was highly variable, increased after cisplatin, and exceeded 150 ml/min/1.73 m2. GFRcysC was less variable and decreased at the end of therapy. AKI biomarkers were elevated indicating acute tubular dysfunction, however, did not differ between 4 and 12 h infusions. Radiographic and histological response were similar for patients receiving 4 h or 12 h infusions; the median percent tumor necrosis was > 95%. CONCLUSIONS: Reducing peak serum and urine MTX concentration by prolonging the infusion duration did not alter risk of acute kidney injury. GFRcysC was decreased at the end of therapy. Proteinuria and elevations in AKI biomarkers indicate that direct tubular damage contributes to HDMTX nephrotoxicity. CLINICAL TRIAL: NCT01848457.
Authors: Brigitte C Widemann; Frank M Balis; Beate Kempf-Bielack; Stefan Bielack; Charles B Pratt; Stefano Ferrari; Gaetano Bacci; Alan W Craft; Peter C Adamson Journal: Cancer Date: 2004-05-15 Impact factor: 6.860
Authors: Alexander J Chou; Eugenie S Kleinerman; Mark D Krailo; Zhengjia Chen; Donna L Betcher; John H Healey; Ernest U Conrad; Michael L Nieder; Michael A Weiner; Robert J Wells; Richard B Womer; Paul A Meyers Journal: Cancer Date: 2009-11-15 Impact factor: 6.860
Authors: S Ferrari; E Palmerini; E Staals; M E Abate; A Longhi; M Cesari; A Balladelli; L Pratelli; G Bacci Journal: J Chemother Date: 2009-04 Impact factor: 1.714
Authors: Neyssa M Marina; Sigbjørn Smeland; Stefan S Bielack; Mark Bernstein; Gordana Jovic; Mark D Krailo; Jane M Hook; Carola Arndt; Henk van den Berg; Bernadette Brennan; Bénédicte Brichard; Ken L B Brown; Trude Butterfass-Bahloul; Gabriele Calaminus; Heike E Daldrup-Link; Mikael Eriksson; Mark C Gebhardt; Hans Gelderblom; Joachim Gerss; Robert Goldsby; Allen Goorin; Richard Gorlick; Holcombe E Grier; Juliet P Hale; Kirsten Sundby Hall; Jendrik Hardes; Douglas S Hawkins; Knut Helmke; Pancras C W Hogendoorn; Michael S Isakoff; Katherine A Janeway; Heribert Jürgens; Leo Kager; Thomas Kühne; Ching C Lau; Patrick J Leavey; Stephen L Lessnick; Leo Mascarenhas; Paul A Meyers; Hubert Mottl; Michaela Nathrath; Zsuzsanna Papai; R Lor Randall; Peter Reichardt; Marleen Renard; Akmal Ahmed Safwat; Cindy L Schwartz; Michael C G Stevens; Sandra J Strauss; Lisa Teot; Mathias Werner; Matthew R Sydes; Jeremy S Whelan Journal: Lancet Oncol Date: 2016-08-25 Impact factor: 41.316
Authors: Laura B Ramsey; Frank M Balis; Maureen M O'Brien; Kjeld Schmiegelow; Jennifer L Pauley; Archie Bleyer; Brigitte C Widemann; David Askenazi; Sharon Bergeron; Anushree Shirali; Stefan Schwartz; Alexander A Vinks; Jesper Heldrup Journal: Oncologist Date: 2017-10-27